$2.97
▲ +0.3% Today
as of Aug 5, 16:52 ET
Last 30 days
Recent Press Releases & News
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience: Q2 Earnings Snapshot
Overview
52-week range
$3.40
$15
0% of range
Avg surprise (last 3)
+72.2%
Avg reaction (last 2)
-0.0%
50% positive
Latest IV / EM
201%
EM ±33.6% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $0.07 | $0.06 | +16.7% | +75.0% | +3.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.05 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.04 | $0.02 | +100.0% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.04 | $0.02 | +100.0% | — | -3.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | — | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.03 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | — | $34M | $31M | $30M | — | $26M | $23M |
| Cost of revenue | $11M | — | $12M | $11M | $11M | — | $9M | $9M |
| Gross profit | $20M | — | $22M | $20M | $19M | — | $16M | $14M |
| Operating income | $2M | — | $4M | $3M | $5M | — | $2M | $-256,000 |
| Net income | $6M | — | $5M | $4M | $5M | — | $2M | $-15,000 |
| EPS (diluted) | $0.07 | — | $0.05 | $0.04 | $0.06 | — | $0.02 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $64M | $60M | $56M | — | $32M | $28M |
| Inventory | $24M | $20M | $19M | $14M | $11M | $9M | $11M | $12M |
| Total current assets | $105M | $97M | $94M | $87M | $76M | $64M | $52M | $49M |
| Total assets | $114M | $106M | $98M | $92M | $81M | $68M | $57M | $54M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $32M | $30M | $27M | $27M | $26M | $22M | $22M | $23M |
| Total equity | $82M | $77M | $71M | $64M | $55M | $46M | $34M | $31M |